Price of bevacizumab for intravitreal injection in New Zealand

Clinical and Experimental Ophthalmology

Volumn 38, Issue 1, 2010, Pages 84-

  Abeysiri, Poorna ^a   Johnston, Nicholas R ^a   Molteno, Anthony C B ^a  

^a DUNEDIN HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG INDICATION; ENDOPHTHALMITIS; HEALTH CARE SYSTEM; HUMAN; LETTER; NEW ZEALAND; PUBLIC HEALTH SERVICE; SHELF LIFE; SYRINGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG COSTS; HUMANS; INJECTIONS; NEW ZEALAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77950927784     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02196.x     Document Type: Letter

References (5)

1. Avastin-bevacizumab - Core Data Sheet version 13.0 (11 November 2008). 2008, http://medsafe.govt.nz/profs/Datasheet/a/Avastininf.htm, Medsafe, Accessed September 2009. Available from:
2. Arias L, Caminal JM, Casas L. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008, 92:1636-41.
3. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008, 18:255-62.
4. Beutel J, Peters S, Lüke M. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2008, Early View Published Online: 22 Sep 2008
5. Arevalo JF, Wu L, Sanchez JG. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009, 23:117-23.